PTGX Operating Income
$58.34MTTM · USD
Period ending:
PTGX FY Operating IncomeUSD
$252.84M-$158.13M
2014-12-312025-12-31
Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.
PTGX operating income history
Profit from core business operations before interest and taxes. The available annual fiscal periods series contains 12 observations from Dec 31, 2014 to Dec 31, 2025.
| Period ending | Operating Income (USD) |
|---|---|
| -158,127,000 | |
| 252,843,000 | |
| -93,652,000 | |
| -131,373,000 | |
| -125,845,000 | |
| -64,516,000 | |
| -80,521,000 | |
| -42,269,000 | |
| -37,897,000 | |
| -32,666,000 | |
| -14,794,000 | |
| -9,319,000 |
Compare operating income
Other companies in Health Care. Each page shows its own reporting periods and currency.
- Guardant Health Inc (GH) operating income
- Bridgebio Pharma Inc (BBIO) operating income
- Brightspring Health Services Inc (BTSG) operating income
- Madrigal Pharmaceuticals Inc (MDGL) operating income
- Ensign Group Inc (ENSG) operating income
- Glaukos Corp (GKOS) operating income
- Vaxcyte Inc (PCVX) operating income
- Krystal Biotech Inc (KRYS) operating income
All PTGX financial metrics · PTGX stock overview · How to interpret financial metrics
